Q-omics provides the consensus-scored MIR548I2 profile across patient tissues and cancer cell-line models. MIR548I2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR548I2 is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, MIR548I2 RNA expression shows 10,391 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UCS, STAD, and ESCA as cancer lineages where MIR548I2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR548I2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR548I2 survival associations across molecular data types. MIR548I2 RNA expression shows survival associations in the most cancer types (9), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR548I2 RNA expression–survival associations across cancer types. High MIR548I2 expression shows unfavorable associations in MESO, LIHC, CESC, BLCA and ESCA, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .013). Together, the overview and detailed table identify UCS as the clearest survival context for MIR548I2 RNA expression.
This table summarizes MIR548I2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR548I2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR548I2 shows lower tumor expression in UCEC, LUSC and COAD and higher tumor expression in STAD. The STAD box plot shows higher MIR548I2 RNA expression in tumor versus normal tissue (log2 FC = +0.956, t-test p < 0.001).
This table shows molecular features associated with MIR548I2 in patient tissues and cancer cell lines. In patient samples, MIR548I2 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
